Norma Sofía Torres Pabón

Prof. Dr. Norma Sofía Torres Pabón

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 August 2021 in Polymers
Verified
Journal Article
Open access
PDF file
VGVíctor Guarnizo-Herrero
Víctor Guarnizo-Herrero
CSCarlos Torrado Salmerón
Carlos Torrado Salmerón
NPNorma Sofía Torres Pabón
Norma Sofía Torres Pabón
GDGuillermo Torrado Durán
Guillermo Torrado Durán
JMJavier Morales
Javier Morales
FFFacultad Farmacia
Facultad Farmacia
This study investigated the combination of different proportions of cationic chitosan and anionic carboxymethyl cellulose (CMC) for the development of polyelectrolyte complexes to be used as a carrier in a sustained-release system. Analysis via scanning electron microscopy (SEM) Fourier transform infrared spectroscopy (FTIR), differential scanning calorimetry (DSC), and powder X-ray diffraction (PXRD) confirmed ionic interactions occur between the chitosan and carboxymethyl cellulose chains, which increases drug entrapment. The results of the dissolution study in acetate buffer (pH 4.2) showed significant increases in the kinetic profiles of clarithromycin for low proportions of chitosan/carboxymethyl cellulose tablets, while the tablets containing only chitosan had high relaxation of chitosan chains and disintegrated rapidly. The Korsmeyer–Peppas kinetic model for the different interpolymer complexes demonstrated that the clarithromycin transport mechanism was controlled by Fickian diffusion. These results suggest that the matrix tablets with different proportions of chitosan/carboxymethyl cellulose enhanced the ionic interaction and enabled the prolonged release of clarithromycin.

22 October 2023 in Polymers
Verified
Journal Article
Open access
PDF file
CPCelia López-Manzanara Pérez
Celia López-Manzanara Pérez
NPNorma Sofía Torres Pabón
Norma Sofía Torres Pabón
ACAlmudena Laguna Castro
Almudena Laguna Castro
GDGuillermo Torrado Durán
Guillermo Torrado Durán
Paloma Marina de la Torre-IglesiasPaloma Marina de la Torre-Iglesias
Paloma Marina de la Torre-Iglesias
CSCarlos Torrado Salmerón
Carlos Torrado Salmerón
Simvastatin (SIM) is a potent lipid-lowering drug used to control hyper-cholesterolemia and prevent cardiovascular diseases. SIM presents low oral bioavailability (5%) because of its low aqueous solubility. In this work, polyelectrolyte complexes (PEC) are developed with different chitosan (CS) and carboxymethylcellulose (CMC) ratios that will allow for an increase in the SIM dissolution rate (2.54-fold) in simulated intestinal medium (pH 4.5). Scanning Electron Microscopy (SEM) images revealed highly porous structures. The changes between both complexes, PEC-SIM:CS:CMC (1:1:2) and (1:2:1), were related to the relaxation of the polymer chains upon absorption of the dissolution medium. Fourier-transform infrared spectroscopy (FTIR), differential scanning calorimetry (DSC) and powder X-ray diffraction (XRPD) studies were used to evaluate the polymer/polymer and drug/polymer interactions on the different PEC-SIM:CS:CMC ratios. In addition, the PEC-SIM:CS:CMC (1:2:1) complex exhibited a high ratio of protonated amino groups (NH3+) and an increase in intramolecular hydrogen bonds, which were correlated with a high expansion of the interpolymer chains and an increase in the SIM dissolution rate. Different kinetic models such as zero-order, first-order, Higuchi and Korsmeyer–Peppas were studied to evaluate the influence of CS/CMC ionic interactions on the ability to improve the release rate of poorly soluble drugs.

8 January 2024 in Heliyon
Verified
Journal Article
Open access
BMBorja Martínez-Alonso
Borja Martínez-Alonso
NPNorma Sofía Torres Pabón
Norma Sofía Torres Pabón
MFMaría Isabel Fernández-Bachiller
María Isabel Fernández-Bachiller
GDGuillermo Torrado Durán
Guillermo Torrado Durán
RCRocío González Crespo
Rocío González Crespo
Mª Ángeles Peña FernándezMª Ángeles Peña Fernández
Mª Ángeles Peña Fernández
Ferric hexacyanoferrate, Fe4 [Fe(CN)6]3 · xH2O, known as Prussian blue (PB), has proven its effectiveness as an antidote in cases of accidental poisoning or poisoning caused by radioactive materials such as cesium (Cs) and thallium (Tl); which due to their solubility in water, when absorbed by the human body, cause serious damage to vital organs. The local development of a drug with PB as an active ingredient arises as a response to the civil and military needs established within the Ministry's pharmacy request for national defense. This fact contemplates the circumstances related to public health protection in the nuclear, radiological, biological and chemical (NRBQ) of the emergency institutions in health and national security. In this paper and by using various analytical techniques, the characterization of the locally synthesized PB with pharmaceutical quality has been described, as a first step to predict its behavior in the preparation of a drug that contains it as an active ingredient.

22 September 2023 in Ars Pharmaceutica (Internet)
Verified
Journal Article
Open access
PDF file
Mª Ángeles Peña FernándezMª Ángeles Peña Fernández
Mª Ángeles Peña Fernández
GSGaia Spanò
Gaia Spanò
NPNorma Sofía Torres Pabón
Norma Sofía Torres Pabón
Fleming MartinezFleming Martinez
Fleming Martinez
Introduction: Solubility studies and obtaining physicochemical data on drugs in pure solvents belonging to different chemical classes are key to developing new drug formulations. In this work, Hansen partial solubility parameters (HSP) were calculated to assess the miscibility and intermolecular interactions of barnidipine in seventeen pure solvents. The comparison of the results obtained with the theoretical values ​​calculated according to the structure of barnidipine, were valuable to analyse the influence of the solute-solute, solute-solvent relationships of the additive contribution groups, on the chemical and physical properties of this molecule with the solvents of different polarity tested, to provide relevant information highly useful in the pharmaceutical industry. Method: Equilibrium barnidipine solubilities in mono-solvents was determined using the classical shake-flask method, followed by UV-spectrophotometric analysis at 298.15 K. The partial solubility parameters were calculated by applying theoretical group contribution methods, proposed by Hoftyzer-Van Krevelen and Fedors. The KAT-LSER model was used to investigate the effect of solvent based on the concept of linear solvation energy relationships. The mole fraction was obtained from the densities of the solutions. Solid-phase analyses were made by calorimetry differential scanning. Results: The modification introduced in the extended Hansen method, that is, the use of lnX2 as the dependent variable, provided excellent results. The highest solubility values have been found in polar solvents. It is observed that solvent-solvent and solute-solvent intermolecular interactions through hydrogen bonds and van der Waals forces, significantly influence drug solubility. Conclusions: The affinity between barnidipine and each one of the selected solvent was evaluated by using HSP. Results showed that HSP could be well used to analyse drug solubility in particular solvents. Barnidipine is easier to dissolve in solvents with shorter carbon chains and higher polarity.

1 November 2023 in Saudi Pharmaceutical Journal
Verified
Journal Article
Open access
JAJuan de Dios Azorín Abraham
Juan de Dios Azorín Abraham
GDGuillermo Torrado Durán
Guillermo Torrado Durán
NPNorma Sofía Torres Pabón
Norma Sofía Torres Pabón
Antonio Peña-FernándezAntonio Peña-Fernández
Antonio Peña-Fernández
Mª Ángeles Peña FernándezMª Ángeles Peña Fernández
Mª Ángeles Peña Fernández
Potassium iodide (KI) is a treatment to neutralize radioactive agents that could be inhaled or ingested in nuclear incidents. The inorganic salt KI constitutes a source of iodine, which in the body acts by accumulating in the thyroid gland, producing its saturation, and thus preventing the fixation of radioactive iodine species. In Spain, the Military Defence Pharmacy Centre (CEMILFARDEF) was challenged to develop this antidote to be distributed among the population surrounding nuclear power plants, in only one new solid pharmaceutical form for oral administration, in order to replace the two pharmaceutical forms available, which are capsules for adults and oral solution for children, considered less versatile. A selection of excipients was carried out to achieve pharmacotechnical behaviour suitable for the industrial manufacture of potassium iodide in tablets, complying with the pre-established process and finished product quality parameters. The development allowed the preparation of three industrial-sized batches on which the stability of the developed formulation was studied. An uncoated 65 mg double-scored potassium iodide tablet was developed using easily accessible excipients in the formulation and direct compression as the manufacturing method. The formula complied with the stability tests, with which the development carried out can respond to the eventual demand that its elaboration would entail in the event of nuclear incidents. The developed formulation of a 65 mg double-scored potassium iodide tablet allows the great variability of user needs, from infants to adults with a single pharmaceutical form, which additionally implies logistical benefits in distribution, stock control and appropriate renewal according expiration dates, among the population surrounding nuclear power plants and available to deployed military personnel, in the event of potential nuclear incidents.

17 October 2025 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
BABorja Martínez Alonso
Borja Martínez Alonso
GDGuillermo Torrado Durán
Guillermo Torrado Durán
NPNorma Sofía Torres Pabón
Norma Sofía Torres Pabón
Mª Ángeles Peña FernándezMª Ángeles Peña Fernández
Mª Ángeles Peña Fernández
Background/Objectives: Given the persistent threat of war and nuclear accidents, and the global reliance on marketed Prussian blue capsules manufactured in only a few countries without an openly accessible quantitative formulation, there is a critical need for robust tablet alternatives that ensure stability, scalability, and rapid deployment. This study focuses on the design and development of PB tablets for oral administration as decorporation agents for radioactive and toxic species, particularly for treatment in nuclear and radiological emergencies. Methods: Advanced tableting processes, including direct compression, wet granulation, and dry granulation, were employed to develop innovative Prussian blue tablet formulations and to provide significant flexibility for industrial-scale production. Comprehensive physicochemical and pharmacotechnical characterizations were performed to support the formulation and to ensure both the safety and efficacy of the PB tablets. Stability studies were conducted in accordance with ICH guidelines to evaluate product performance over time and to confirm that quality and performance attributes remained within specification. Results: Among the formulations evaluated, the direct compression (DC5) was recommended for industrial production due to its simplicity, short cycle time, and high throughput. Stability studies up to 18 months confirmed that the PB tablets remained within specification, and the program is ongoing at 24, 36, 48, and 60 months. Conclusions: This research provides a promising advancement in countermeasures for nuclear and radiological incidents by delivering a robust, scalable PB tablet formulation that can be rapidly manufactured and deployed in emergency situations.